Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Cost and Compliance Dominate Agenda for 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.
Jan 2, 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.

Pharma Faces New Political Landscape

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.
Dec 2, 2010

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.

Comparative Research Poses Challenges

A new center may provide evidence for improving care, but could discourage coverage of treatments.
Nov 2, 2010

A new center may provide evidence for improving care, but could discourage coverage of treatments.

Administration Seeks to Modernize Vaccine Production

President Obama and HHS eye innovation and countermeasures to protect public health.
Oct 2, 2010

President Obama and HHS eye innovation and countermeasures to protect public health.

FDA Struggles with Risk Management and Drug Safety

Weighing the pros and cons of REMS for bringing risky products to market.
Sep 2, 2010

Weighing the pros and cons of REMS for bringing risky products to market.

Manufacturing Failures Place GMP Compliance in Spotlight

Fallout escalates from McNeil recall and Genzyme shortages as regulators review oversight.
Aug 2, 2010

Fallout escalates from McNeil recall and Genzyme shortages as regulators review oversight.

Transparency to Alter FDA and Industry Practices

More information may be released to improve public understanding of regulatory policies.
Jul 2, 2010

More information may be released to improve public understanding of regulatory policies.

Securing the Supply Chain

FDA and industry seek to ensure drug quality and safety in a world complicated by global outsourcing and rising theft.
Jun 2, 2010

FDA and industry seek to ensure drug quality and safety in a world complicated by global outsourcing and rising theft.

Health Reform to Transform Coverage, Costs

Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.
May 2, 2010

Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here